BofA analyst Jason Gerberry downgraded Exelixis (EXEL) to Neutral from Buy with a $39 price target
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- FDA tells Exelixis supplemental NDA for cabozantinib to be discussed in March
- Exelixis director Poste sells 30,000 common shares
- Exelixis general counsel Hessekiel sells 50,000 common shares
- Biotech Alert: Searches spiking for these stocks today
- Exelixis price target raised to $33 from $32 at Guggenheim